Transgene

Report Publication Announcement • Dec 21, 2017

Transgene Announces Financial Calendar for 2018

Strasbourg, France, December 21, 2017, 6:00 p.m. CET - Transgene (Euronext Paris: TNG) today announced its financial reporting dates for 2018:

March 21:	2017 Fiscal Year Results
April 26:	First Quarter 2018 Financial Results
May 23:	Annual Shareholders' Meeting
September 19:	First Half 2018 Financial Results
October 25:	Third Quarter 2018 Financial Results

Contacts

Transgene:	Media contacts:
Lucie Larguier	Citigate Dewe Rogerson
Director Corporate Communications & IR	David Dible / Marine Perrier
+33 (0)3 88 27 91 04	+ 44 (0)20 7638 9571
investorrelations@transgene.fr	transgene@citigatedr.co.uk

About Transgene

Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company's lead clinical-stage programs are: TG4010, a therapeutic vaccine against non-small cell lung cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a therapeutic vaccine against HPV-positive head and neck cancers. The Company has several other programs in clinical and preclinical development, including TG1050 (chronic hepatitis B) and TG6002 (solid tumors). Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China.

Additional information about Transgene is available at www.transgene.fr. Follow us on Twitter: @TransgeneSA